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The pathogenesis of acute exacerbation of idiopathic pulmonary ﬁbrosis (IPF) remains to be elucidated. To evaluate the roles of
inﬂammatory mediators in acute exacerbation, the concentrations of high mobility group protein B1 (HMGB1), a chief mediator
of acute lung injury, and 18 inﬂammatory cytokines were measured in the bronchoalveolar lavage ﬂuid, serially sampled from
seven IPF patients after the onset of acute exacerbation. HMGB1 gradually increased in the alveolar ﬂuid after the onset of
acute exacerbation, in positive correlation with monocytes chemotactic protein-1 (MCP-1), a potent ﬁbrogenic mediator. In the
lung tissues of eight IPF patients autopsied after acute exacerbation, intense cytoplasmic staining for HMGB1 was observed in
the alveolar epithelial cells in alveolar capillary augmented lesions, where the capillary endothelial cells remarkably reduced the
expressionofthrombomodulin,anintrinsicantagonistofHMGB1.TheseresultssuggestpathogenicrolesforHMGB1andMCP-1
in the late phase of acute exacerbation of IPF.
1.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is one of the most
refractory of all lung diseases lacking eﬀective therapy [1].
Not only progressive pulmonary ﬁbrosis but also acute
exacerbation, deﬁned as clinically signiﬁcant deterioration
of unidentiﬁable cause, is attributed to the poor survival of
these patients [2]. In the pathologic ﬁndings in the lungs of
IPFpatientsaﬄictedwithacuteexacerbation,diﬀusealveolar
damage, which is consistent with the ﬁndings observed
after acute lung injury from various causes [2], is the
most characteristic underlying usual interstitial pneumonia.
However, the etiology of acute exacerbation of IPF has yet to
be elucidated.
HighmobilitygroupproteinB1(HMGB1)wasoriginally
identiﬁedasanuclearnonhistoneproteinwithDNA-binding
domains and implicated as an important endogenous danger
signaling molecule [3]a sw e l la sal a t em e d i a t o ro fs y s t e m i c
inﬂammation in septic shock [4, 5], thus having a puta-
tive role in the pathogenesis of acute lung injury [6, 7].2 Pulmonary Medicine
In addition, several studies have identiﬁed the B-box domain
of HMGB1 as important for many of the proinﬂammatory
properties of HMGB1, including cytokine release [8, 9].
HMGB1 is released passively during cellular necrosis by
almost all cells which have a nucleus and signals to neigh-
boring cells in the case of ongoing damage [5]. However,
HMGB1 also is secreted actively by immune cells such as
monocytes, macrophages, and dendritic cells [4, 10, 11]. The
receptor for advanced glycation end products (RAGE) was
the ﬁrst receptor demonstrated to bind HMGB1 [12], and
HMGB1 signaling through RAGE was found to promote
chemotaxis and the production of cytokines in a process
thatinvolvestheactivationofthetranscriptionfactornuclear
factor-κB(NF -κB)[13,14].Nevertheless,thecontributionof
HMGB1 in the pathogenesis of acute exacerbation of IPF has
not been determined yet.
We previously reported the heterogeneous remodeling of
CD34-positive alveolar capillaries in the lungs of patients
with IPF [15]. The alveolar capillaries were decreased in
ﬁbrotic lesions, but increased in nonﬁbrotic alveolar septa
around the ﬁbrotic lesions, where VEGF and IL-8, potent
angiogenic factors, were augmented [15] .S i n c eV E G Fi sa l s o
apotentinducerofvascularpermeability[16],thesecapillary
dense lesions in nonﬁbrotic alveolar septa are considered
to be leaky, and thus susceptible to the alveolar inﬁltra-
tion triggered by inﬂammatory mediators in acute lung
injury [17]. We are also interested in thrombomodulin, an
endothelial anticoagulant cofactor, which is highly expressed
in alveolar capillaries in normal control lungs but less so
in IPF lungs [15]. This is because the N-terminal domain
of thrombomodulin binds HMGB1 so as to prevent its
interaction with RAGE and thus suppresses the induction of
proinﬂammatory events [18].
In this context, we examined the bronchoalveolar lavage
ﬂuid serially sampled from patients with IPF after acute
exacerbation, along with the lung tissue specimens, biopsied
from patients with stable IPF and autopsied from IPF
patients who died after acute exacerbation, to evaluate the
involvement of inﬂammatory mediators in the pathogenesis
of acute exacerbation of IPF.
2.MaterialsandMethods
Clinical Samples. Acute exacerbation of idiopathic pul-
monary ﬁbrosis was diagnosed according to the Japanese
diagnostic criteria established in 2004 [19], which are
essentially compatible with the criteria by the Idiopathic
Pulmonary Fibrosis Clinical Research Network Investigators
in 2007 [2]. Bronchoalveolar lavage ﬂuid was sampled at
Tosei General Hospital from seven patients with IPF after
two to four instances of acute exacerbation in each patient
to allow for the diagnostic exclusion of infection, and the
samples were stored at −80◦C degrees. The surgical biopsies
of ten patients with stable IPF, and the autopsied lungs of
eight patients with IPF who died after acute exacerbation,
were obtained at Tohoku University Hospital. The disease-
free lung tissues autopsied from three patients without
any chronic lung diseases were also examined as controls.
These lung tissues were ﬁxed in 10% buﬀered formalin and
imbedded in paraﬃn wax. The written informed consent
obtained from the patients for using these clinical samples
was approved by the ethics committee of Tohoku University.
Measurement of HMGB1 and Cytokines. HMGB1 in BALF
was measured by a highly sensitive and speciﬁc ELISA
method (Shino-test, Kanagawa, Japan) [20], as reported
previously [6, 7]. In brief, black polystyrene microtiter
plates (Corning Laboratory Science, Corning, NY) were
coated with anti-HMGB1 polyclonal antibody in phosphate-
buﬀered saline (PBS), washed 3 times with PBS containing
0.05% Tween-20, and blocked by PBS-1% bovine serum
albuminfor2hours.Afterwashing,100μlof8dilutionseach
of the standard and samples, 1:1 dilutions in 0.2mol/L Tris
(pH 6.5), 0.15mol/L NaCl containing 1% BSA were added to
the wells and incubated for 24 hours at room temperature.
After washing, antihuman HMGB1 peroxidase-conjugated
monoclonal antibody was added and incubated at room
temperature for 30 minutes. After another washing step, PS-
atto (Lumigen, Southﬁeld, MI) was added, and its lumines-
cence was measured with a 9000D microplate luminescence
reader (DIA-IATRON, Tokyo, Japan). The concentrations of
17cytokinesintheseBALFsamples,consistingofInterleukin
(IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-17,
granulocyte colony stimulating factor (G-CSF), monocytes
chemotactic protein-1 (MCP-1), granulocyte/macrophage-
colony stimulating factor (GM-CSF), macrophage inﬂam-
matory protein (MIP)-1β, interferon (IFN)-γ,a n dt u m o r
necrosis factor (TNF-α), were determined using Bio-Plex
(Bio-Rad Laboratories Inc.) following the manufacturer’s
protocol. The total TGF-β1 in these BALF samples was also
measured using the enzyme immunoassay (EIA) produced
by MBC Laboratories, Inc. (Tokyo, Japan).
Virus Isolation. Each BALF sample was subjected to virus
isolation by the microplate method [21] at the Virus
Research Center at the National Hospital Organization
(Sendai, JAPAN). In short, the specimen was placed in
transport medium composed of Eagle’s minimum essential
medium (Sigma, St. Louis, MO, USA) with 0.5% gelatin
containing 500units/ml of penicillin G and 500mg/ml
of streptomycin and was centrifuged at 4,000g at 4◦C
for 15min. The supernatant fraction was inoculated into
cultured cells of human embryonic ﬁbroblasts, using the cell
lines, HEp-2; Vero; HMV-II, MDCK, LLC-MK2 cells, which
can support the growth of numerous viruses, including
respiratory syncytial virus, inﬂuenza viruses, parainﬂuenza
viruses, enteroviruses, adenoviruses, cytomegalovirus, her-
pes simplex virus, rhinovirus, mumps virus, measles virus,
human coronavirus 229E, and human metapneumovirus.
After inoculation, cytopathic eﬀects were examined daily for
two weeks, and, furthermore, when no CPE was found, blind
passage was performed once for another two weeks with
the same system. RT-PCR was also performed for human
metapneumovirus virus isolation [22].
Immunohistochemistry. Tissue sections of 3μm thickness
were deparaﬃnized and treated with a peroxidase-blocking
reagent (DAKO, Carpinteria, CA) for 10 minutes at roomPulmonary Medicine 3
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Figure 1: Inﬂammatory mediators in the BALF of IPF patients after acute exacerbation. (a) The concentrations of inﬂammatory mediators
in the BALF of a 69-year-old male (an ex-smoker, Brickman index = 400) on days 1, 2, 13, and 21 after steroid therapy against acute
exacerbation. He had been followed up without immunosuppressive therapy against IPF before administration to the hospital. No
mechanical ventilator was used for treatment. He died 5 months later. (b) A 67-year-old female (a nonsmoker, no previous treatment
for IPF) diagnosed with acute exacerbation 3 days after “ﬂu-like” phenomena and died 3 months later. No mechanical ventilator was
used for treatment. (c) The pooled data of the HMGB1 concentration in 16 BALF samples obtained from 7 patients showed a gradual
increase of HMGB1 even after the steroid therapy for acute exacerbation (r = 0.64, P = .008). (d) Among the 18 cytokines in the BALF
samples examined, only MCP-1 was increased in positive correlation with HMGB1 (r = 0.58, P = .0176) after the steroid therapy for acute
exacerbation.4 Pulmonary Medicine
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Figure 2: Immunohistochemical HMGB1 expression in lung tissues. (a) Intense cytoplasmic and nuclear staining HMGB1 was observed in
alveolar macrophages and alveolar epithelial cells in the lungs of patients with IPF who died after acute exacerbation (HMGB1 in brown,
bar = 50μm). (b) and (c) The immunoreactive cells for HMGB1 were distributed in the alveolar damaged lesions in which the alveolar
capillaries were increased (CD34 in red and HMGB1 in brown; scale bars: 100μmi n( b )a n d5 0μm in (c)). (d) In the surgical lung biopsies
of the IPF patients (d) revealed only nuclear staining for HMGB1 (HMGB1 in brown; scale bar: 50μm). The sections were counterstained
with Elastica-Goldner staining, showing the elastic ﬁbers in purple and collagen in light blue ((b)–(d)).
temperature before incubation with the primary antibodies.
The antibodies and the optimal dilutions used in this study
were as follows: monoclonal antibodies against human
HMGB1 (1:3,000, Shino-test), the same antibody used for
ELISA, RAGE (MAB5328, 1:50, CHEMICON International,
Inc., Temecula, CA), thrombomodulin (TM1009, 1:100,
DAKO Company Ltd., Glostrup, Denmark), CD34 (4A1,
1:100, Nichirei Co., Tokyo, Japan), and antihuman von
Willebrand factor (vWF) monoclonal antibody (F8/86,
1:1,000, Nichirei). The tissues were incubated with a
primary antibody in a moist chamber at 4◦C for overnight
and were further reacted with a polymer reagent (ENVISON
kit; DAKO, Carpinteria, CA) for 60 minutes at room
temperature. For double immunohistochemical staining,
the antigen-antibody complex was visualized with Vector
Red (Vector Laboratories, Burlingame, CA) or 1mM
3.3 -diaminobenzidine (DAB), as described previously [15].
Morphometric Evaluation. The percentages of the distribu-
tion area of the cells immunoreactive for thrombomodulin
amongthoseimmunoreactive forCD34 wereestimated from
30 randomly selected color images at a magniﬁcation of 400
in each case using a digital image analysis system (Lumina
Vision, Mitani Corporation, Fukui, Japan).
StatisticalAnalysis. Foranalysisoftwounpairedsamples,the
nonparametricMann-WhitneyU testwasused.Asigniﬁcant
diﬀerence was deﬁned as P<. 05. All values were represented
as the means ± SEM.
3. Results
3.1. Cytokines in BALF after Acute Exacerbation. The bron-
choalveolar lavage ﬂuid (BALF) that we examined in this
study was serially sampled two to four times after acute
exacerbation from each IPF patient (n = 8). Although
all of these patients were treated with steroid therapy after
the diagnosis of acute exacerbation (Day 1), none of these
patients were mechanically ventilated during the treatment.
We measured the concentrations of HMGB1 and 18 otherPulmonary Medicine 5
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Figure 3: Quantitative distribution of HMGB1-positive cells in lung tissues. (a) The distribution patterns of the cells positive for HMGB1
were quantiﬁed in the autopsied lung tissues after acute exacerbation in 8 IPF patients (AEx IPF), using the biopsied lung tissues of 10
patients with stable IPF and three controls. (b) The percentages of immunoreactive cells with nuclear or cytoplasmic staining for HMGB1
are shown. The cells with both cytoplasmic and nuclear staining for HMGB1 were counted as cytoplasmic.
inﬂammatory cytokines, consisting of IL-1β,I L - 2 ,I L - 4 ,I L -
5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-17, G-CSF, MCP-1, GM-
CSF, MIP-1β,I F N - γ,T N F - α,a n dT G F −β. The ﬁndings in
two of these seven patients are illustrated (Figures 1(a)
and 1(b)). Although the concentration of HMGB1 in BALF
was low in the early phase of acute exacerbation, HMGB1,
and MCP-1 as well, continued increasing even after steroid
therapy. The pooled data (16 samples from 7 patients)
of the HMGB1 concentration in the BALF of these seven
patients also revealed a gradual increase of HMGB1 after
acute exacerbation (Figure 1(c)). Among the inﬂammatory
cytokines examined in these BALF samples, only MCP-1 was
increased in positive correlation with HMGB1 (Figures 1(a)
and 1(d)).
Our attempts at virus isolation in the BALF specimens
sampled after acute exacerbation did not uncover any of
the usual pathogenic bacteria or viruses, such as respiratory
syncytial virus, inﬂuenza viruses, parainﬂuenza viruses,
enteroviruses, adenoviruses, rhinovirus, cytomegalovirus,
herpes simplex virus, coronavirus, mumps virus, or metap-
neumovirus (data not shown).
3.2. HMGB1 Producing Cells in Lung Tissue. The immuno-
histochemical expression of HMGB1 in the lung tissues of
18 patients with IPF was compared between two patient
groups: the autopsied lung tissues of eight patients who had
who died after acute exacerbation and the surgically biopsied
lung tissues of ten patients with stable IPF. In the autopsied
lung tissues, intense cytoplasmic staining for HMGB1 was
observed in most of alveolar macrophages and alveolar
epithelialcellswithorwithoutnuclearstaining(Figure 2(a)).
Double immunostaining for HMGB1 and CD34, a marker
of alveolar capillary endothelial cells [15], clearly revealed
the distribution of these cells, with an intense expression of
HMGB1 near the capillary augmented alveolar septa that
were without apparent ﬁbrosis (Figures 2(b) and 2(c)). In
contrast, only nuclear staining for HMGB1 was observed
in the surgical lung biopsies of the patients with stable IPF
(Figure 2(d)).
The average percentage of the cells immunoreactive
for HMGB1 was 48.9 ± 2.51% (mean ± SEM) in the
autopsiedlungtissuesofIPFpatientsafteracuteexacerbation
(Figure 3). In the surgical biopsies of patients with stable
IPF, 33.3 ± 5.6% of the cells were positive for HMGB1
without a signiﬁcant diﬀerence compared with the autopsies
(P = .057); however, most of these cells with HMGB1
immunoreactivity in the case of the surgical biopsies
exhibited nuclear staining (Figure 2(d)) along with rare
cytoplasmic staining (2.19 ±0.46%), which was signiﬁcantly
diﬀerentcomparedwiththepercentageofnuclearstainingin
autopsies (24.5 ±7.0%, P<. 001) (Figure 3).
3.3. Expression of MCP-1, RAGE, and Thrombomodulin.
The distribution of the cells immunoreactive for HMGB1
was compared with that of MCP-1 and RAGE, one of
the main receptors for HMGB1, in the postmortem lung
tissues of patients with IPF and acute exacerbation. The
cells producing MCP-1 coincided with the cells having
cytoplasmic HMGB1 expression (Figures 4(a) and 4(b)),
while the intense expression of RAGE was chieﬂy observed in
epithelial cells and to a lesser extent in capillary endothelial
cells (Figures 4(c) and 4(d)).
The alveolar capillaries which were immunoreactive
for CD34 expression (Figure 5(a)) and thrombomodulin6 Pulmonary Medicine
(a) (b)
(c) (d)
Figure 4: Distribution of HMGB1, MCP1 and RAGE in the lungs after acute exacerbation. The cells immunoreactive for HMGB1 (a) and
MCP-1 (b) in the consecutive sections of the autopsied lung tissues of IPF patients who died after acute exacerbation (bars = 100μm). The
intense immunoreactivity of RAGE, the receptor of HMGB1, was observed in type I alveolar epithelial cells in these lungs ((c) and (d)) ((c),
bar = 100μm; (d), bar = 10μm). The sections were counterstained with Elastica-Goldner staining, showing the elastic ﬁbers in purple and
collagen in light blue ((a)–(d)).
(Figure 5(b)) were revealed in consecutive sections of a typi-
calcaseofsurgicalbiopsies.Theimmunor eacti vityofthr om-
bomodulin was almost always sustained in CD34-positive
alveolar capillaries. In contrast, the endothelial expression
of thrombomodulin was apparently decreased in the autop-
sied lung tissues of IPF patients after acute exacerbation
(Figures 5(c) and 5(d)). Morphometric analysis using a
digital image analyzer system clearly revealed the decrease of
immunoreactivity for thrombomodulin compared to CD34
in the autopsied lung tissues of IPF patients died after acute
exacerbation (26.1 ± 7.2%, n = 8) in comparison with
controls (89.7 ± 13.8%, n = 3) and even with the biopsied
lung tissues from stable IPF patients (66.5 ±9.0%, n = 10).
No signiﬁcant diﬀerence was found between the stable IPF
patients and normal controls in terms of thrombomodulin
reactivity against CD34 (Figure 5(e)).
4. Discussion
This is the ﬁrst report of a persistent elevation of HMGB1
and MCP-1 after the onset of acute exacerbation in the lungs
of patients with IPF. Both of these mediators were produced
by alveolar macrophages and alveolar type II epithelial
cells distributed in the capillary-increased alveolar lesions
in which the capillary endothelial cells exhibited reduced
expression of thrombomodulin, an intrinsic antagonist of
HMGB1 [18].
The gradual increase of HMGB1 in the bronchoalveolar
lavage ﬂuid after the onset of acute exacerbation suggests
several plausible roles in the pathogenesis of acute exac-
erbation of IPF. One of the roles of HMGB1 is as a late
mediator of acute exacerbation, because the concentration
of HMGB1 was low at the initial onset of acute exacerbation.
Although no virulent organisms or viruses were detected in
the bronchoalveolar lavage ﬂuids examined in this study, all
of these patients had ﬂu-like symptoms a few days before
the onset of acute exacerbation, which can cause a trigger-
like eﬀect of fulminating inﬂammation similar to acute lung
injury. The gradual increase of HMGB1 in the epithelial
lining ﬂuids in the lungs after the initial onset of lung
injury was also reported in both experimental and clinical
acute lung injury [6]. Although HMGB1 can be released byPulmonary Medicine 7
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Figure 5: Distribution of alveolar capillary endothelial cells positive for thrombomodulin in stable IPF, acute exacerbation of IPF and
controls. (a) and (b) The lung tissues which were surgically biopsied from a patient with stable IPF were double immunostained for
HMGB1 (in brown) and CD34 (in red) (a). The consecutive sections were stained for HMGB1 (in brown) and thrombomodulin (in red)
(b) (bars = 100μm). (c) and (d) The lung tissues which were obtained by autopsy from a patient who died after acute exacerbation were
double immunostained for HMGB1 (in brown) and CD34 (in red) (c) or thrombomodulin (in red) (d) in the consecutive sections (bars
= 100μm). (e) The percentages of the distribution areas of the capillary endothelial cells immunoreactive for thrombomodulin per those
immunoreactive for CD34 were evaluated by a digital image analyzer and compared among stable IPF (n = 10), acute exacerbation (AEx
IPF, n = 8) of IPF, and controls (n = 3).
macrophages in response to viral infection [23], the gradual
increase of HMGB1 observed in this study is considered to
be induced by passive release from necrotic alveolar type
II epithelial cells [5] and by active secretion from alveolar
macrophages in response to TNFα,I L - 1 ,I F N γ, and oxidative
stress without proved molecular mechanisms [24–26]. This
is because HMGB1 increased in the absence of virulent
virus and because the cytoplasmic staining of HMGB1 was
signiﬁcantly increased in these cells after acute exacerbation.
In contrast to the role promoting severe inﬂammation,
H M G B 1h a sb e e nr e p o r t e dt op r o m o t et i s s u er e p a i ra n d
regeneration [27]. Importantly, HMGB1 induces the migra-
tion of stem cells toward inﬂamed regions to promote repair
and regeneration [28]. For example, in smooth muscle cells,
HMGB1 induces proliferation and rapid changes in cellular
architecture, resulting in cell migration [29, 30]. Interest-
ingly, many of these restorative eﬀects are mediated through
the same receptors (e.g., RAGE) that mediate the proin-
ﬂammatory properties of the molecule [29]. Considering a
recentreportthatthelossofRAGEcontributestopulmonary
ﬁbrosis [31], the increase of HMGB1 in alveolar ﬂuids itself
may induce ﬁbrogenesis through other HMGB1 receptors,
such as the Toll-like family of receptors (TLRs), TLR4,
TLR2, or TLR9 [32, 33]. The gradual increase of MCP-1
in positive correlation with HMGB1 in alveolar ﬂuids after
acute exacerbation may also contribute to ﬁbroproliferation8 Pulmonary Medicine
[34, 35], which is thought to be involved in the regenerative
eﬀects of HMGB1. Of course, we cannot deny at this point
the plausibility that treatment, including steroid therapy,
for these patients in the hospital after the onset of acute
exacerbation might aﬀect the gradual increase of HMGB1.
In addition, the correlation of the concentration of HMGB1
and/or MCP-1 in BALF with the disease severity of acute
exacerbation of IPF has been left for expectations.
We observed that the cells with cytoplasmic expression of
HMGB1weredistributedinthealveolarcapillaryaugmented
lesions [15] in which the endothelial cells displayed reduced
expression of thrombomodulin, an intrinsic antagonist of
HMGB1 [18], after acute exacerbation. As we reported
previously, even though neutrophils could be origin of
HMGB1 in acute lung injury [7], in addition to alveolar
epithelial cells and alveolar macrophages, the concentration
of HMGB1 beside capillaries should be elevated. These
capillary augmented lesions in IPF patients are susceptible to
acute lung injury, not only because these capillaries reduce
the ability to antagonize HMGB1 but also because VEGF,
which is elevated (augmented) in these lesions [15], loosens
the tight junctions of endothelial cells so as to induce leakage
[36, 37]. The decreased expression of thrombomodulin,
which is an anticoagulant [38] as well, may readily induce
coagulation in these capillary augmented lesions, which
frequently occurs in cases of acute exacerbation in IPF
patients [39].
We conclude from these results that HMGB1 and MCP-1
are increased in the lungs of IPF patients after acute exac-
erbation and that the alveolar capillary augmented lesions
with decreased expression of thrombomodulin, an intrinsic
inhibitor of HMGB1, may exacerbate alveolar damage and
ﬁbrogenesis.
Acknowledgments
This work was supported in part by Grant-in-Aid for
Scientiﬁc Research by Japan Society for the Promotion of
Science (no. 22390164 to M. Ebina) and by a grant to the
Diﬀuse Lung Diseases Research Group from the Ministry of
Health, Labor and Welfare of Japanese Government (to M.
Ebina).
References
[ 1 ]W .D .T r a v i s ,T .E .K i n g ,E .D .B a t e m a ne ta l . ,“ A m e r i c a n
thoracic society/European respiratory society international
multidisciplinary consensus classiﬁcation of the idiopathic
interstitial pneumonias,” American Journal of Respiratory and
Critical Care Medicine, vol. 165, no. 2, pp. 277–304, 2002.
[ 2 ]H .R .C o l l a r d ,B .B .M o o r e ,K .R .F l a h e r t ye ta l . ,“ A c u t e
exacerbations of idiopathic pulmonary ﬁbrosis,” American
Journal of Respiratory and Critical Care Medicine, vol. 176, no.
7, pp. 636–643, 2007.
[3] J. R. Klune, R. Dhupar, J. Cardinal, T. R. Billiar, and A. Tsung,
“HMGB1: endogenous danger signaling,” Molecular Medicine,
vol. 14, no. 7-8, pp. 476–484, 2008.
[4] H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late
mediator of endotoxin lethality in mice,” Science, vol. 285, no.
5425, pp. 248–251, 1999.
[5] P.Scaﬃdi, T.Misteli,andM.E.Bianchi,“Release ofchromatin
protein HMGB1 by necrotic cells triggers inﬂammation,”
Nature, vol. 418, no. 6894, pp. 191–195, 2002.
[6] H. Ueno, T. Matsuda, S. Hashimoto et al., “Contributions of
high mobility group box protein in experimental and clinical
acute lung injury,” AmericanJournal of Respiratory and Critical
Care Medicine, vol. 170, no. 12, pp. 1310–1316, 2004.
[7] E. N. Ogawa, A. Ishizaka, S. Tasaka et al., “Contribution of
high-mobility group box-1 to the development of ventilator-
induced lung injury,” American Journal of Respiratory and
Critical Care Medicine, vol. 174, no. 4, pp. 400–407, 2006.
[8] J. Li, R. Kokkola, S. Tabibzadeh et al., “Structural basis for the
proinﬂammatory cytokine activity of high mobility group box
1,” Molecular Medicine, vol. 9, no. 1-2, pp. 37–45, 2003.
[9] D. Messmer, H. Yang, G. Telusma et al., “High mobility
group box protein 1: an endogenous signal for dendritic cell
maturationandTh1polarization,”JournalofImmunology,vol.
173, no. 1, pp. 307–313, 2004.
[10] M. T. Lotze and K. J. Tracey, “High-mobility group box 1
protein (HMGB1): nuclear weapon in the immune arsenal,”
Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005.
[ 1 1 ]E .A b r a h a m ,J .A r c a r o l i ,A .C a r m o d y ,H .W a n g ,a n dK .J .
Tracey, “Cutting edge: HMG-1 as a mediator of acute lung
inﬂammation,” Journal of Immunology, vol. 165, no. 6, pp.
2950–2954, 2000.
[12] O. Hori, J. Brett, T. Slattery et al., “The receptor for advanced
glycation end products (RAGE) is a cellular binding site
for amphoterin. Mediation of neurite outgrowth and co-
expression of RAGE and amphoterin in the developing
nervous system,” The Journal of Biological Chemistry, vol. 270,
no. 43, pp. 25752–25761, 1995.
[13] R. Palumbo, B. G. Galvez, T. Pusterla et al., “Cells migrating to
sitesoftissuedamageinresponsetothedangersignalHMGB1
require NF-κB activation,” J o u r n a lo fC e l lB i o l o gy , vol. 179, no.
1, pp. 33–40, 2007.
[ 1 4 ]J .S .P a r k ,J .A r c a r o l i ,H .K .Y u me ta l . ,“ A c t i v a t i o no fg e n e
expression in human neutrophils by high mobility group box
1 protein,” American Journal of Physiology, vol. 284, no. 4, pp.
C870–C879, 2003.
[15] M. Ebina, M. Shimizukawa, N. Shibata et al., “Heterogeneous
increase in CD34-positive alveolar capillaries in idiopathic
pulmonary ﬁbrosis,” American Journal of Respiratory and
Critical Care Medicine, vol. 169, no. 11, pp. 1203–1208, 2004.
[16] S. Fischer, T. Gerriets, C. Wessels et al., “Extracellular RNA
mediatesendothelial-cellpermeabilityviavascularendothelial
growth factor,” Blood, vol. 110, no. 7, pp. 2457–2465, 2007.
[17] M. Mura, C. C. Dos Santos, D. Stewart, and M. Liu, “Vascular
endothelial growth factor and related molecules in acute lung
injury,” Journal of Applied Physiology, vol. 97, no. 5, pp. 1605–
1617, 2004.
[18] K. Abeyama, D. M. Stern, Y. Ito et al., “The N-terminal
domain of thrombomodulin sequesters high-mobility group-
B1 protein, a novel antiinﬂammatory mechanism,” Journal of
Clinical Investigation, vol. 115, no. 5, pp. 1267–1274, 2005.
[19] H. Taniguchi, M. Ebina, Y. Kondoh et al., “Pirfenidone in
idiopathic pulmonary ﬁbrosis,” European Respiratory Journal,
vol. 36, no. 3, pp. 695–696, 2010.
[20] S. Yamada, K. Inoue, K. Yakabe, H. Imaizumi, and I.
Maruyama, “High mobility group protein 1 (HMGB1) quan-
tiﬁed by ELISA with a monoclonal antibody that does not
cross-react with HMGB2,” Clinical Chemistry, vol. 49, no. 9,
pp. 1535–1537, 2003.Pulmonary Medicine 9
[21] Y.Numazaki,T.Oshima,A.Ohmietal.,“Amicroplatemethod
for isolation of viruses from infants and children with acute
respiratory infections,” Microbiology and Immunology, vol. 31,
no. 11, pp. 1085–1095, 1987.
[22] A. Suzuki, O. Watanabe, M. Okamoto et al., “Detection of
human metapneumovirus from children with acute otitis
media,” Pediatric Infectious Disease Journal,v o l .2 4 ,n o .7 ,p p .
655–657, 2005.
[23] W. Jiang, C. W. Bell, and D. S. Pisetsky, “The relationship
between apoptosis and high-mobility group protein 1 release
frommurinemacrophagesstimulatedwithlipopolysaccharide
or polyinosinic-polycytidylic acid,” Journal of Immunology,
vol. 178, no. 10, pp. 6495–6503, 2007.
[24] B. Rendon-Mitchell, M. Ochani, J. Li et al., “IFN-γ induces
high mobility group box 1 protein release partly through a
TNF-dependentmechanism,”JournalofImmunology,vol.170,
no. 7, pp. 3890–3897, 2003.
[25] A. Rouhiainen, J. Kuja-Panula, E. Wilkman et al., “Regulation
of monocyte migration by amphoterin (HMGB1),” Blood, vol.
104, no. 4, pp. 1174–1182, 2004.
[26] D. Tang, Y. Shi, R. Kang et al., “Hydrogen peroxide stimulates
macrophages and monocytes to actively release HMGB1,”
Journal of Leukocyte Biology, vol. 81, no. 3, pp. 741–747, 2007.
[27] M. E. Bianchi and A. A. Manfredi, “High-mobility group box
1 (HMGB1) protein at the crossroads between innate and
adaptive immunity,” Immunological Reviews, vol. 220, no. 1,
pp. 35–46, 2007.
[28] R. Palumbo and M. E. Bianchi, “High mobility group box
1 protein, a cue for stem cell recruitment,” Biochemical
Pharmacology, vol. 68, no. 6, pp. 1165–1170, 2004.
[29] B. Degryse, T. Bonaldi, P. Scaﬃdi et al., “The high mobility
group (HMG) boxes of the nuclear protein HMG1 induce
chemotaxis and cytoskeleton reorganization in rat smooth
muscle cells,” Journal of Cell Biology, vol. 152, no. 6, pp. 1197–
1206, 2001.
[30] A. Porto, R. Palumbo, M. Pieroni et al., “Smooth muscle cells
in human atherosclerotic plaques secrete and proliferate in
response to high mobility group box 1 protein,” The FASEB
Journal, vol. 20, no. 14, pp. 2565–2566, 2006.
[31] J. M. Englert, L. E. Hanford, N. Kaminski et al., “A role for
thereceptorforadvancedglycationendproductsinidiopathic
pulmonary ﬁbrosis,” American Journal of Pathology, vol. 172,
no. 3, pp. 583–591, 2008.
[32] J. S. Park, F. Gamboni-Robertson, Q. He et al., “High
mobility group box 1 protein interacts with multiple Toll-like
receptors,” American Journal of Physiology, vol. 290, no. 3, pp.
C917–C924, 2006.
[33] J. Tian, A. M. Avalos, S. Y. Mao et al., “Toll-like receptor 9-
dependent activation by DNA-containing immune complexes
is mediated by HMGB1 and RAGE,” Nature Immunology, vol.
8, no. 5, pp. 487–496, 2007.
[34] B. B. Moore, M. Peters-Golden, P. J. Christensen et al.,
“Alveolar epithelial cell inhibition of ﬁbroblast proliferation is
regulated by MCP-1/CCR2 and mediated by PGE,” American
Journal of Physiology, vol. 284, no. 2, pp. L342–L349, 2003.
[35] I. Inoshima, K. Kuwano, N. Hamada et al., “Anti-monocyte
chemoattractant protein-1 gene therapy attenuates pul-
monary ﬁbrosis in mice,” American Journal of Physiology, vol.
286, no. 5, pp. L1038–L1044, 2004.
[36] S. Fischer, T. Gerriets, C. Wessels et al., “Extracellular RNA
mediatesendothelial-cellpermeabilityviavascularendothelial
growth factor,” Blood, vol. 110, no. 7, pp. 2457–2465, 2007.
[37] M. Mura, C. C. dos Santos, D. Stewart, and M. Liu, “Vascular
endothelial growth factor and related molecules in acute lung
injury,” Journal of Applied Physiology, vol. 97, no. 5, pp. 1605–
1617, 2004.
[38] C. T. Esmon, “The roles of protein C and thrombomodulin in
the regulation of blood coagulation,” The Journal of Biological
Chemistry, vol. 264, no. 9, pp. 4743–4746, 1989.
[39] H.Kubo,K.Nakayama,M.Yanaietal.,“Anticoagulanttherapy
for idiopathic pulmonary ﬁbrosis,” Chest, vol. 128, no. 3, pp.
1475–1482, 2005.